# Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

> **NCT00750555** · PHASE2 · TERMINATED · sponsor: **Geisinger Clinic** · enrollment: 4 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00750555
- **Lead sponsor:** Geisinger Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** PI Law left Geisinger-study terminated prematurely - 4 patients enrolled
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750555, "Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00750555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*